# Neoadjuvant PD-1 Monoclonal Antibody Plus Cisplatin-based Chemotherapy in Locally Advanced Upper Tract Urothelial Carcinoma

> **NCT04672317** · PHASE2 · UNKNOWN · sponsor: **RenJi Hospital** · enrollment: 20 (actual)

## Conditions studied

- Neoadjuvant Therapy of Locally Advanced Upper Urinary Tract Urothelial Carcinoma

## Interventions

- **DRUG:** Immunotherapy combined with chemotherapy

## Key facts

- **NCT ID:** NCT04672317
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-10
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-06-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04672317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04672317, "Neoadjuvant PD-1 Monoclonal Antibody Plus Cisplatin-based Chemotherapy in Locally Advanced Upper Tract Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04672317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*